The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The reporting odds ratio and its advantages over the proportional reporting ratio
Abstract
Purpose: The proportional reporting ratio (PRR) is the proportion of spontaneous reports for a given drug that are linked to a specific adverse outcome, divided by the corresponding proportion for all or several other drugs. The PRR is similar to the proportional mortality ratio (PMR), an old epidemiologic measure calculated from death registries and constructed in similar fashion to the PRR. The PMR has important deficiencies, however, which the PRR shares. Miettinen and Wang demonstrated that the PMR could be improved by reformulating it as an odds ratio and applying the principles of a case‐control study to the measure. In this paper, we review the problem with the PRR and show how the corresponding odds ratio represents an improvement over the PRR. Methods: The method used is discussion and illustration by way of a hypothetical example. Results: The PRR does not estimate relative risk. If, however, a spontaneous report database is viewed as source data for a case‐control study, the reporting odds ratio (ROR) can be used to estimate relative risk. Treating the data as source data for a case‐control study allows for further reduction of bias by the judicious choice of controls. Conclusions: Calculating the ROR in spontaneous report databases offers advantages over the PRR. It allows for estimation of the relative risk, and focuses attention on which people or reports should be included or excluded from the control series, permitting more deliberate elimination of biases. It also highlights the inherent weaknesses in spontaneous report data, which become more evident in light of the usual principles of control selection in case‐control studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
AN ALTERNATIVE TO THE PROPORTIONATE MORTALITY RATIO
MIETTINEN, O. S., & WANG, J.-D. (1981) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113161 · Cited by 233
van der Heijden, P. G. M., van Puijenbroek, E., van Buuren, S., & van der Hofstede, J. W. (2002) · Statistics in Medicine · doi:10.1002/sim.1157 · Cited by 136
Moore, N. D., Hall, G. C., Sturkenboom, M., Mann, R., Lagnaoui, R., & Bégaud, B. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.848 · Cited by 117
Temporal Patterns of NSAID Spontaneous Adverse Event Reports
Wallenstein, E. J., & Fife, D. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00006 · Cited by 61
Research works printed but not linked: 1
- Weber JCP, 1984, Epidemiology of adverse reactions to nonsteroidal antiflammatory drugs, Adv Inflam Res, 6, 1
Cited by
Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30608-9 · Cited by 1,271
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Montastruc, J., Sommet, A., Bagheri, H., & Lapeyre‐Mestre, M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04037.x · Cited by 517
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F., & Moore, N. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 268
Cardiovascular Toxicities Associated With Ibrutinib
Salem, J.-E., Manouchehri, A., Bretagne, M., Lebrun-Vignes, B., Groarke, J. D., Johnson, D. B., Yang, T., Reddy, N. M., Funck-Brentano, C., Brown, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.056 · Cited by 266
Zhou, C., Peng, S., Lin, A., Jiang, A., Peng, Y., Gu, T., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101967 · Cited by 213
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Cutroneo, P. M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., Moretti, U., et al. (2024) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2023.1323057 · Cited by 224
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Montano, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.756633 · Cited by 70
Fukazawa, C., Hinomura, Y., Kaneko, M., & Narukawa, M. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4672 · Cited by 57
Ocular Safety Profile of BRAF and MEK Inhibitors
Mettler, C., Monnet, D., Kramkimel, N., Tréluyer, J.-M., Mouthon, L., Brézin, A., Dupin, N., Valnet-Rabier, M.-B., Chouchana, L., & Terrier, B. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.05.008 · Cited by 40
Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0329 · Cited by 40
Montastruc, F., Scotto, S., Vaz, I. R., Guerra, L. N., Escudero, A., Sáinz, M., Falomir, T., Bagheri, H., Herdeiro, M. T., Venegoni, M., et al. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000094 · Cited by 33
Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01594-7 · Cited by 26
Ortland, I., Mirjalili, M., Kullak-Ublick, G. A., & Peymani, P. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20503 · Cited by 16
Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database
Luo, J., Zeng, Y., Chen, Z., Luo, Y., Shi, L., & Zhou, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1498204 · Cited by 9
Wang, Z., Mei, H., Song, B., & Shi, Z. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110638 · Cited by 6
Li, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
Metadata
- Authors
- Rothman, K. J., Lanes, S., & Sacks, S. T.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 13
- Issue
- 8
- Pages
- 519-523
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2158299492
- Cited by
- 1,111
- References
- 6
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.